Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Entera Bio (ENTX) Equity Ratio (2017 - 2025)

Entera Bio has reported Equity Ratio over the past 9 years, most recently at 0.82 for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio fell 4.8% year-over-year to 0.82, compared with a TTM value of 0.82 through Dec 2025, down 4.8%, and an annual FY2025 reading of 0.82, down 4.8% over the prior year.
  • Equity Ratio came in at 0.82 for Q4 2025, down from 0.88 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.92 in Q3 2022 to a low of 0.73 in Q3 2023.
  • Median Equity Ratio over the past 5 years was 0.87 (2023), compared with a mean of 0.86.
  • The sharpest move saw Equity Ratio surged 43.97% in 2021, then dropped 20.94% in 2023.
  • Over 5 years, Equity Ratio stood at 0.87 in 2021, then grew by 3.12% to 0.9 in 2022, then fell by 1.41% to 0.88 in 2023, then dropped by 2.53% to 0.86 in 2024, then fell by 4.8% to 0.82 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Equity Ratio are 0.82 (Q4 2025), 0.88 (Q3 2025), and 0.88 (Q2 2025).